首页|Clinical value of modified Shenling Baizhu powder(加味参苓白术散)in treating targeted therapy-induced diarrhea in non-small cell lung cancer

Clinical value of modified Shenling Baizhu powder(加味参苓白术散)in treating targeted therapy-induced diarrhea in non-small cell lung cancer

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Clinical value of modified Shenling Baizhu powder(加味参苓白术散)in treating targeted therapy-induced diarrhea in non-small cell lung cancer
OBJECTIVE:To assess clinical value of modified Shenling Baizhu powder(加味参苓白术散,SBP)in intervening targeted therapy-induced diarrhea.METHODS:This study was a prospective randomized controlled study.Eighty-five non-small cell lung cancer(NSCLC)patients with diarrhea who took targeted drugs were randomly divided into two groups.The experimental group received modified SBP,while the control group received imodium.During 2 courses of treatment(1 week/course)and 2 weeks of follow-up,we observed remission and recurrence of diarrhea,as well as the improvement of Karnofsky score(KPS)in the two groups and drug safety.RESULTS:Eighty cases were completed,with 40 cases in the experimental group and 40 cases in the control group.The control group's diarrhea remission rate was significantly lower than the experimental group's(P＜0.05).After 2 courses of treatment,the symptom scores of both groups were lower than before,with that of the experimental group remarkably lower(P＜0.05).Furthermore,the experimental group experienced less abdominal fullness and appetite loss than the control group(P＜0.05).There was no prominent difference in overall diarrhea recurrence,time,or KPS after treatment between the two groups(P＞0.05).No unique adverse events occurred in experimental group or control group.CONCLUSION:The modified SBP could improve targeted therapy-induced diarrhea in NSCLC,and is superior to imodium in relieving diarrhea,improving related symptom scores and symptoms,with no obvious drug-related adverse events.

carcinoma,non-small-cell lungtargeted therapy-induced diarrheadiarrhea remission rateadverse eventsmodified Shenling Baizhu powder

WANG Ming、ZHENG Yun

展开 >

Department of Thoracic Surgery,Shulan(Hangzhou)Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College,Hangzhou 310000,China

Thoracic Oncology Department,Shulan(Hangzhou)Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College,Hangzhou 310000,China

carcinoma,non-small-cell lung targeted therapy-induced diarrhea diarrhea remission rate adverse events modified Shenling Baizhu powder

2024

10.19852/j.cnki.jtcm.20240806.008

中医杂志(英文版)
中国中医药学会 中国中医研究院

中医杂志(英文版)

影响因子：0.855
ISSN：0255-2922
年,卷(期)：2024.44(5)